| Dec'17 | Dec'16 | Dec'15 | Dec'14 | |||
|---|---|---|---|---|---|---|
IPO [Member] | ||||||
Private Placement [Member] | ||||||
Operating activities: | ||||||
Net loss | ||||||
-96,388 | -12,545 | -8,052 | -3,013 | |||
Adjustments to reconcile net loss to net cash from operating activities: | ||||||
Research and development expense settled by shares issuance | ||||||
42,259 | 0 | 0 | - | |||
Share-based compensation | ||||||
22,683 | 0 | 0 | - | |||
Excess cost for acquisition of an equity investee | ||||||
0 | 0 | 814 | 0 | |||
Net loss on equity method investment | ||||||
0 | 0 | -44 | -97 | |||
Imputed interest | ||||||
0 | 0 | 532 | 826 | |||
Depreciation expense | ||||||
32 | 18 | 10 | 0 | |||
Loss on disposal of property and equipment | ||||||
0 | 0 | -27 | 0 | |||
Changes in operating assets and liabilities: | ||||||
Advances to suppliers | ||||||
726 | 710 | 73 | 16 | |||
Prepaid expenses and other current assets | ||||||
-96 | 334 | 22 | 2 | |||
Other noncurrent assets | ||||||
240 | 121 | 0 | 0 | |||
Accounts payable | ||||||
2,935 | 144 | 94 | 45 | |||
Accrued expenses | ||||||
699 | -102 | 210 | 0 | |||
Amounts due to related parties | ||||||
-210 | -222 | -168 | 870 | |||
Other current liabilities | ||||||
64 | 174 | 14 | 47 | |||
Net cash used in operating activities | ||||||
-28,796 | -13,698 | -6,570 | - | |||
Investing activities: | ||||||
Net cash used in operating activities | ||||||
- | - | - | -1,146 | |||
Acquisitions of property and equipment | ||||||
76 | 64 | 40 | 0 | |||
Purchase of short-term investments | ||||||
3,074 | 0 | 0 | - | |||
Net cash used in investing activities | ||||||
-3,150 | -64 | 355 | - | |||
Financing activities: | ||||||
Loans to related parties | ||||||
0 | 0 | 861 | 960 | |||
Cash obtained from acquisition of an equity investee | ||||||
0 | 0 | 1,256 | 0 | |||
Net cash used in investing activities | ||||||
- | - | - | -960 | |||
Proceeds from issuance of ordinary shares, net of underwriting discount | ||||||
50,505 | 15,250 | 16,000 | 0 | |||
Proceeds from a third party loan | ||||||
0 | 0 | 1,000 | 0 | |||
Proceeds from loans due to related parties | ||||||
0 | 0 | 1,273 | 2,498 | |||
Repayment of loans due to related parties | ||||||
0 | 0 | 402 | 0 | |||
Cash distribution to equity owner in the Internal Restructuring | ||||||
0 | 0 | 1,201 | 0 | |||
Payment of offering costs | ||||||
2,783 | 537 | 0 | 0 | |||
Net cash provided by financing activities | ||||||
47,722 | 14,713 | 16,670 | - | |||
Effect of foreign exchange rate changes, net | ||||||
18 | -85 | -26 | - | |||
Net cash (used in) provided by financing activities | ||||||
- | - | - | 2,498 | |||
Effect of foreign exchange rate changes, net | ||||||
- | - | - | -8 | |||
Net increase/(decrease) in cash | ||||||
15,794 | 866 | 10,429 | 384 | |||
Non-cash activities: | ||||||
Ordinary shares issued to acquire Wanchun Pharma | ||||||
0 | 0 | 2,400 | 0 | |||
Deemed contribution through the Internal Restructuring | ||||||
0 | 0 | 9,393 | 0 | |||
Initial public offering costs accrued in accrued expenses and other current liabilities | ||||||
0 | 1,324 | 0 | 0 | |||
Research and development expense settled by shares issuance | ||||||
42,259 | 0 | 0 | - | |||
Net settlement of related party loans | ||||||
0 | 0 | 1,800 | 0 | |||